Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Risk of recurrence and competing mortality in older patients
New indication concerns maintenance treatment of adult patients with advanced BRCA1/2-mutated high-grade epithelial ovarian cancer
The frequency of administration of bone-treating agents did not affect Quality of Life outcomes
Integrated molecular analyses shed light on alterations correlated with disease progression and therapeutic resistance in metastatic breast cancer
It is indicated for the treatment of advanced cutaneous squamous cell carcinoma
The results of the ANNOUNCE study show that olaratumab with doxorubicin does not prolong the lives of patients with soft tissue sarcoma
It received a positive opinion for the treatment of adult patients with germline BRCA1/2 mutations who have HER2-negative locally advanced or metastatic breast cancer
A biobank of ovarian cancer organoids provide resource for research and precision medicine
Results fromtheTARGET, I-PREDICT and WINTHER studies released
Approval is based on results from the KEYNOTE‑426 study
Systemic absorption is of concern because it may result in side effects such as venous thromboembolism, stroke and endometrial cancer
Approval of FGFR inhibitor is based on data from a cohort of patients enrolled on Study BLC2001
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
